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Abstract
Background: In order to elucidate a combination of genetic alterations that drive tobacco carcinogenesis we have explored
a unique model system and analytical method for an unbiased qualitative and quantitative assessment of gene-gene and
gene-environment interactions. The objective of this case control study was to assess genetic predisposition in a biologically
enriched clinical model system of tobacco related cancers (TRC), occurring as Multiple Primary Neoplasms (MPN).
Methods: Genotyping of 21 candidate Single Nucleotide Polymorphisms (SNP) from major metabolic pathways was
performed in a cohort of 151 MPN cases and 210 cancer-free controls. Statistical analysis using logistic regression and
Multifactor Dimensionality Reduction (MDR) analysis was performed for studying higher order interactions among various
SNPs and tobacco habit.
Results: Increased risk association was observed for patients with at least one TRC in the upper aero digestive tract (UADT)
for variations in SULT1A1 Arg
213His, mEH Tyr
113His, hOGG1 Ser
326Cys, XRCC1 Arg
280His and BRCA2 Asn
372His. Gene -
environment interactions were assessed using MDR analysis. The overall best model by MDR was tobacco habit/p53(Arg/
Arg)/XRCC1(Arg
399His)/mEH(Tyr
113His) that had highest Cross Validation Consistency (8.3) and test accuracy (0.69). This
model also showed significant association using logistic regression analysis.
Conclusion: This is the first Indian study on a multipathway based approach to study genetic susceptibility to cancer in
tobacco associated MPN. This approach could assist in planning additional studies for comprehensive understanding of
tobacco carcinogenesis.
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Introduction
Tobaccorelated cancers(TRC) whichinclude carcinomaoflung,
esophagus, head-neck, cervix, bladder, stomach, kidney, pancreas,
liver and myeloid leukemia account for almost half the global
burden of cancer [1,2]. Tobacco contains a variety of chemical
carcinogens which are activated for detoxification by xenobiotic
metabolism enzymes (XME).Activated carcinogenscancauseDNA
damage by forming harmful DNA adducts. The damaged DNA is
repaired by elaborate DNA repair machinery. Cells with extensive
DNA damage usually undergo apoptosis. Compromise in any of
these cellular pathways promotes survival and growth of mutated
cells leading to oncogenesis [3].
Genetic susceptibility could be an important determinant in TRC
etiology as suggested by familial occurrence of TRC [4].
Identification and characterization of susceptibility factors in
common multifactor disorders such as TRC is challenging. This is
due to stringent requirement of appropriate samples to analyze the
complex gene-environment interactions involved, limitations of
conventional statistical methods to reliably determine gene-gene and
gene-environment interaction and tools to correlate the genotype to
phenotype. Genes important in carcinogenesis are highly polymor-
phic and contribute to cancer susceptibility. There are numerous
large studies associating single nucleotide polymorphisms (SNPs)
in a single gene or multiple genes in a single pathway. Often such
variants have limited use in assessment of disease risk, since most of
the variants have low penetrance and confer a relatively small risk.
Multipathway based association study should help to identify a
cumulative effect of low penetrance alleles in predisposition [5].
Consensushasfailedtoemergeregarding the combination of genetic
alterations that drives tobacco carcinogenesis. There is no report yet
on a multipathway based approach to study genetic susceptibility to
cancer in tobacco associated multiple primary neoplasms (MPN).
In the present case-control study, we have investigated the
hypothesis thatcumulative effectoflow penetrancealleles predispose
to tobacco induced MPN (Fig. 1). It is believed that patients with
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30013MPN provide a genetically enriched resource to study predisposition
to cancer [6]. Association of 21 candidate SNPs in 18 genes from
pathways of xenobiotic metabolism, DNA repair, cell cycle
regulation and apoptosis implicated in tobacco carcinogenesis was
studied in a unique group of individuals with tobacco related MPN.
Theriskassociationwasanalyzedusinglogisticregressionandhigher
order genetic interactions were studied using multifactor dimension-
ality reduction (MDR) analysis.
Results
In the present study 151 cases with MPN and 210 cancer-free
controls were analyzed. Using IARC definition of Tobacco
Related Cancer (TRC) these 151 MPN patients were further sub
classified as patients with at least one TRC in the UADT (n=113),
none of the TRC in the UADT (n=17) and those with no TRC
(n=21; Table 1). In all the categories, majority of the cancers were
metachronous, that is, the second primary cancer was diagnosed 6
months or more after diagnosis of first cancer.
Majority of the patients had both cancers in the UADT region.
Patients and controls were mainly from North India, with tobacco
habit. Among the tobacco users, 48.6% cases and 61.4% controls
used smokeless tobacco which was in the form of application of
roasted tobacco (masheri) over gums or chewing a mix of tobacco
with one or more ingredients like lime, betel nut or betel leaf. The
quanta of tobacco consumed were not available for many subjects
as it was self reported information.
The genotype distribution of SNPs was compared in cases using
dominant model (homozygous wild type versus homozygous
variant+heterozygous) and extreme model (homozygous wild type
versus homozygous variant). Selection of these models was done
on the biological plausibility that homozygous and heterozygous
variant conferred risk compared to wild type.
Amongst the 21 SNPs selected from genes in different pathways,
univariate analysis showed risk association in a few genes as shown
in Table 2 and Table S1. Crude OR and OR adjusted to age and
gender were considered for statistically significant association.
Increased risk association was observed for patients with at least
Figure 1. Low penetrance effect of SNPs in carcinogenesis.
doi:10.1371/journal.pone.0030013.g001
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genes, SULT1A1 Arg
213His (Extreme model, OR=6.6, 95% CI
1.47–29.34; Dominant model, OR=1.74, 95% CI 1.07–2.82),
meH Tyr
113His (Extreme model, OR=2.55, 95% CI 1.19–5.47),
DNA repair genes, hOGG1 Ser
326Cys (Dominant model,
OR=1.81, 95% CI 1.12–2.90; Heterozygous OR=1.91, 95%
CI 1.16–3.15), XRCC1 Arg
280His (Dominant model, OR=1.80,
95% CI 1.06–3.08), BRCA2 (Heterozygous OR=1.93, 95% CI
1.11–3.35). In the TRC outside group significant risk association
was observed for xenobiotic metabolizing genes MPO G 2463 A
(Extreme model, OR=8.06, 95% CI 2.16–30.72; Dominant
model, OR=3.66, 95% CI 1.37–9.79), SULT1A1 Arg
213His
(Extreme model, OR=6.92, 95% CI 2.27–20.96; Heterozygous,
OR=7.15, 95% CI 2.34–21.67), protective association was
observed for the cell cycle regulating gene Cyclin D1 A
870G
(Extreme model OR=0.27, 95%CI 0.09–0.723; Heterozygous,
OR=0.26, 95%CI 0.09–0.82).
We have conducted MDR analysis accounting for missing values
[7]andtheone-waytofive-wayinteractionmodelswere considered.
As shown in Table 3, the overall best model across one to five-way
interaction models was habit/p53(Arg
72Arg)/XRCC1(Arg
399His)/
meH(Tyr
113His) that had maximum CVC (Cross validation
consistency) and maximum test accuracy (CVC=8.3; test accura-
cy=0.69). To obtain effect size of individual genotype combination,
OR MDR analysis [8] was conducted for this four-way interaction
model as shown in Table S2. Because the number of individuals for
each combination of genotype and habit was relatively small, only
one variable combination Habit=1, p53 (Arg
72Arg)=0, XRCC1
(Arg
399His)=1, and meH (Tyr
113His)=1 had odds ratio with
significant confidence intervals (OR=3.217; 95% CI 1.201–
10.177).
All the 21 SNPs were analyzed for HWE of which 12 SNPs
were in HWE for the control group where as 9 SNP were not in
HWE. However, all the 3 SNPs (p53 (Arg
72Arg)/XRCC1
(Arg
399His)/mEH (Tyr
113His) which showed significant association
together with tobacco habit in the MDR analysis were in HWE.
SNPs with significant association also showed HWE in controls
group. We perfomed linkage disequilibrium analysis for variants in
XRCC1, NAT2 and BRCA2 and observed significant association
between NAT2 Ile
114Thr and NAT2 Arg
197Gln, NAT2 Ile
114Thr and
NAT2 Gly
286Glu, BRCA2 Asp
991Asn and BRCA2 Asn
372His as shown
in Table S3.
Discussion
In the present case-control study we have examined a set of
biologically plausible SNPs implicated in tobacco carcinogenesis
(Fig. 1). Risk association of these SNPs for tobacco related cancers
has been investigated by using conventional statistics and through
MDR analysis. Though not a consistent finding, each of the SNP
identified by us, and a large number of other SNPs have been
shown to be associated with tobacco related cancers in previous
case-control studies or their meta-analyses [1,9,10,11,12,13]. The
evidence for cumulative effect of various genetic alterations on
metabolic and cellular pathways involved in tobacco carcinogen-
esis although compelling [5], is based on piecemeal evidence from
heterogeneous studies of single or few related SNPs, in a
background of large number of genetic and environmental risk
modifiers. Only few genome-wide association studies (GWAS)
have been conducted for tobacco related cancers so far and these
are yet to provide major leads in tobacco carcinogenesis [14].
It is emerging that for an unbiased qualitative and quantitative
assessment of gene-gene and gene-environment interactions,
clinically relevant insight in tobacco carcinogenesis may not come
from additional studies confirming or refuting risk association of
known SNPs, but through exploration of alternative research
strategies, model systems and analytical methods. Towards this
goal we have incorporated three distinct elements in our study.
Firstly, we have adopted a biologically holistic approach of
examining SNPs in the key genes of major pathways in tobacco
carcinogenesis. We have chosen a biologically enriched clinical
model system of tobacco related multiple primary neoplasms
(MPN-TRC). We had earlier hypothesized [5,10,15,16] that
individuals who develop tobacco related MPN, represent a cohort
of individuals with enhanced gene-environment and gene-gene
interaction. Only recently, the unique biological and statistical
Table 1. Demographics of study subjects.
Category
TRC inside UADT
(n=113) (%)
TRC outside UADT
(n=17) (%)
None TRC
(n=21) (%)
Cancer free controls
(n=210) (%)
Males 75 (66) 3 (18) 6 (29) 137 (65)
Females 38 (34) 14 (82) 15 (71) 73 (34)
Age(years)
Median 50 50 44 46
Range 26–75 31–70 23–79 20–84
Types of MPN
Synchronous 33 (29) 3 (18) 3 (14) NA
Metachronous 80 (71) 14 (82) 18 (86) NA
Tobacco Habit
No habit 15 (13) 8 (47) 11 (52) 21 (10)
Only T 70 (62) 8 (47) 8 (38) 160 (76)
T+A 25 (22) 1 (6) 1 (5) 27 (13)
No information 3 (3) 0 1 (5) 2 (1)
T- Tobacco habit alone either in form of chewing or smoking.
T+A – Tobacco in form of chewing or smoking along with alcohol.
48.6% cases and 61.4% controls used smokeless tobacco in form of masheri.
doi:10.1371/journal.pone.0030013.t001
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Pathway Gene
Polymorphism
(SNP ID)
Biological
Effect
Type of
variation Odds Ratio (95% CI)
Controls/Atleast
one in UADT/TRC
outside UADT
At least one
in UADT P value
TRC outside
UADT P value
Xenobiotic
metabolism
MPO G
2463 A
Promoter region
(rs 2333227)
Decreased
expression and
detoxification
GG 141/70/7 - -
GA 45/34/6 1.52(0.87–2.67) 0.131 2.686
(0.752–9.506)
0.100
AA 10/9/4 1.81(0.64–5.104) 0.218 *8.06
(1.639–38.837)
0.008
GA+AA 55/43/10 1.58(0.94–2.65) 0.076 *3.66
(1.207–11.328)
0.013
SULT1A1 Arg
213His
(rs9282861)
G.A, Decreased
enzyme activity,
thermostability
Arg/Arg 132/60/4 - -
Arg/His 60/43/13 1.58(0.93–2.67) 0.075 *7.15
(2.053–27.244)
,0.001
His/His 2/6/0 *6.6(1.16–48.85) 0.017 0(0–199.144) 1.000
Arg/His+
His/His
62/49/13 *1.74(1.07–2.82) 0.026 *6.92
(1.99–26.336)
,0.001
mEH Tyr
113His
(rs1051740)
Decreased
detoxification
Tyr/Tyr 78/25/6 - -
Tyr/His 95/53/6 1.74(0.96–3.18) 0.054 0.82
(0.223–3.019)
0.772
His/His 22/18/3 *2.55(1.11–5.92) 0.024 1.77
(0.319–8.970)
0.426
Tyr/His+
His/His
117/71/9 *1.89(1.07–3.365) 0.020 1.00
(0.310–3.314)
1.000
DNA Repair hOGG1 Ser
326Cys
(rs1052133
Altered
localization
Ser/Ser 114/49/7 - -
Ser/Cys 62/51/7 *1.91(1.13–3.25) 0.011 1.84
(0.548–6.170)
0.387
Cys/Cys 14/8/3 1.33(0.47–3.66) 0.624 3.49
(0.628–17.735)
0.108
Ser/Cys+
Cys/Cys
76/59/10 *1.81(1.09–3.00) 0.016 2.14
(0.712–6.572)
0.198
XRCC1 Arg
280His
(rs25489)
Defective
localization,
decreased repair
Arg/Arg 157/80/14 - -
Arg/His 33/30/2 1.78(0.98–3.25) 0.055 0.680
(0.101–3.371)
1.000
His/His 4/4/1 1.96(0.40–9.63) 0.451 2.804
(0.11–30.328)
0.363
Arg/His+
His/His
37/34/3 *1.80(1.02–3.20). 0.036 0.91
(0.196–3.632)
1.000
BRCA2 Asn
372His
(rs144848)
Reduced DNA
repair
Asn/Asn 81/30/5 - -
Asn/His 70/50/6 *1.93(1.07–3.49) 0.027 1.389
(0.355–5.529)
0.757
His/His 35/14/4 1.08(0.48–2.43) 0.850 1.851
(0.388–8.608)
0.459
Asn/His+
His/His
105/64/10 1.65(0.95–2.870) 0.070 1.543
(0.461–5.424)
0.590
Cell Cycle
regulation
Cyclin D1 A
870 G
Splice site
(rs 603965)
Nuclear
accumulation
of protein
GG 67/33/11
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highlighted by others [6]. These authors provide empirical
evidence that for MPN of the same organ, the relative risk is
approximately the square of the relative risk as found in the
traditional case-control studies using single primary cancers.
In our study, 75% of the TRC MPN were within the UADT,
which is one continuous epithelial lining exposed to tobacco
carcinogens.
The third aspect of our study is the statistical approaches used.
Studying higher order gene interactions using logistic regression is
laborious and has low statistical power due to very high degrees of
freedom. Hence we used multifactor dimensionality reduction
(MDR) as a complementary statistical approach for studying
higher order interactions among various SNPs analyzed and
tobacco habit. This combination of testing multiple SNPs using
MDR showed 4 factor model of tobacco habit, p53 (Arg
72Arg),
XRCC1 (Arg
399His) and mEH (Tyr
113His) with an OR of 3.217
(95% CI: 1.2–10.18) and cross validation consistency of 8.3 as
strongest risk predictor to MPN. Cross validation consistency
refers to the number of times a particular interaction model is
selected across 10 cross-validation datasets and the best test
accuracy of 0.69. We have taken several approaches to control for
false positive findings which may emerge due to multiple testing.
We further tested the 2–4 MDR genetic models using logistic
regression and found significant association of the models with
tobacco related MPN. The SNPs with significant association in
univariate analysis also showed significant interaction in MDR.
The advantage of this observation is that MDR makes no
assumption about the data distribution and does not require
correction of multiple testing, which is helpful for studies with
small sample size. The controls were matched for ethnicity and
tobacco habit reducing the confounding risk due to ethnicity.
It is biologically plausible that decreased detoxification due to
variant meH Tyr
113His results in increased DNA damage which is
inefficiently repaired by the base excision repair protein XRCC1
(Fig. 2). Presence of Arg
399Gln SNP in an evolutionarily conserved
region of XRCC1, expression of meH, XRCC1 in mucosa of the
upper aerodigestive tract [17,18], protein interaction of BRCA2
and p53 [19] strengthen this model.
Meta-analysis has shown varying effects of XRCC1 Arg
280His in
tobacco related cancers [1,9]. Studies in Chinese lung cancer
(n=108) and Korean gastric cancer population (n=172) showed
significant risk association with Arg/His or His/His genotype
[1,20]. An Indian study [21] on oral cancer observed marginal risk
conferred by His/His. Some studies reported no association of
Arg
280His with esophageal [22], bladder [23], gastric [24,25] and
lung cancer [1] although a few studies showed protection by His/
His genotype in lung cancer [26,27]. We observed stronger risk
association of Arg/His in the patient population with at least one
cancer in UADT-MPN group. Ethnic differences could be one of
the determining factors in risk association, as mean frequency of
His/His reported in Asian population is 13% (range 3–36%)
where as in Caucasians it is 36% (range 2–47%) [10].
The variant meH Tyr
113His which results in 30–50% decreased
enzyme activity [28] has been significantly associated with cancers
of larynx and lung [11,12,29]. Other studies observed no
association with lung [30], head and neck [31] and laryngeal
cancers [26]. Most of the studies show trend towards risk for this
Pathway Gene
Polymorphism
(SNP ID)
Biological
Effect
Type of
variation Odds Ratio (95% CI)
Controls/Atleast
one in UADT/TRC
outside UADT
At least one
in UADT P value
TRC outside
UADT P value
GA 93/55/4 1.20(0.68–2.12) 0.589 *0.262
(0.067–0.943)
0.028
AA 45/27/2 1.22(0.62–2.41) 0.627 0.271
(0.039–1.392)
0.129
GA+AA 138/82/6 1.21(0.71–2.05) 0.530 *0.265
(0.083–0.817)
0.015
doi:10.1371/journal.pone.0030013.t002
Table 2. Cont.
Table 3. MDR analysis.
Model CVC train accuracy test accuracy
Habit 7.6 0.637 0.612
Habit/Cyclin D1 (A
870G)
* 4.2 0.667 0.645
Habit/SULT1A1 (Arg
213His)/XRCC1 (Arg
399His) 5.6 0.723 0.654
Habit/p53 (Arg
72Arg)/XRCC1 (Arg
399His)/mEH (Tyr
113His) 8.3 0.778 0.69
SULTA1 (Arg
213His)/p53 (Arg
72Pro) XRCC1 (Arg
399His)/BRCA2
(Asn
372His)/mEH (Tyr
113His)
7.8 0.855 0.632
Analysis has been repeated 10 times after shuffling the order of individuals and the mean of evaluation measures are presented. The results of the best model are in
bold.
*Habit/SULT1A1 (Arg
213His), SULT1A1 (Arg
213His)/BRCA2 (Asn
372His) and Habit/Cyclin D1 (A
870G) have been selected 1, 4, and 5 times out of 10 repeated analyses,
respectively.
doi:10.1371/journal.pone.0030013.t003
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in combination with other genes in the MPN population.
Dominant and heterozygous models showed significant risk
association of hOGG1 Ser
326Cys SNP in UADT-TRC group.
Studies have reported contrasting observation on risk association
of this SNP in UADT cancers. Recently published Indian studies
[27,32] showed significant protective effect in head-neck cancer
and no association of the hOGG1 Cys/Cys and Ser/Cys variant,
whereas meta-analysis and another study [1] observed risk
associaton of Cys/Cys genotype in lung cancer. Biochemical
evidences support Cys/Cys genotype as risk conferring genotype
due to lower protein activity compared to Ser/Ser variant,
observed in head-neck [33] and lung cancer [34].
The BRCA2 Asn
372His SNP showed significant risk association
for dominant model for at least one TRC in UADT category and
trend for risk in other models in at least one TRC in UADT and
TRC outside UADT categories. The variation is located in the
conserved region of the BRCA2 gene. Not much is known about
the functional role of this SNP and its association in tobacco
related cancers. The SNP has been associated with breast cancers
[35] lymphoma [36], not associated with lung cancer [13,37].
BRCA2 Asn
372His showed higher sensitivity to gamma radiation
along with other polymorphisms in the DNA repair pathway [13].
There are conflicting reports on the risk association of the p53
Arg
72Pro SNP. While most studies report a weak protective
association or no association of the p53 wild type Arg
72Arg
genotype for various cancers [38,39] in our MDR model the Arg/
Arg genotype in combination with the other two genotypes and
tobacco, was associated with the risk of tobacco related MPNs.
Several other studies have shown similar risk association between
the wild type Arg/Arg genotype and breast [40], gastric [41], head
and neck [42] and colorectal cancers [43,44]. It may however be
noted that studies which examined the gene-gene or gene
environment interactions, the protective effect of the p53 Arg
72Pro
variant allele was seen in combination with other genotypes like
the p53 intron 6 diplotype for head and neck cancers [42] and
gastric cancer [41] or with the use of non steroidal anti-
inflammatory drugs in colorectal cancer [44].
Despite the strengthsandbiological plausibility ofthe associations
observed in our study, there are inherent limitations. Reliable
estimation on the quanta of tobacco and alcohol consumed was not
available as it was based on self-reported information. It is quite
likely that several other important gene – gene and gene
environment interactions exist that have not been evaluated in
our study. It is also possible some of the SNPs studied and their
interactions failed to emerge as significant risk association due to the
limited sample size.
This is the first study to examine key SNPs in major metabolic
and biological pathways implicated in tobacco carcinogenesis in
the unique Indian MPN population. This study supports MPN to
be an enriched model to predict cumulative genetic interactions.
We anticipate the relevance of correlating the cumulative effect of
variant genotypes to cellular phenotype in response to tobacco
carcinogens. More importantly, for tobacco carcinogenesis it is
difficult to quantify the redundancy of individual SNP, genes and
pathways and this may vary in different geo-ethnic groups due to
significant differences in the frequency of specific SNPs and or
exposure to environmental, dietary co-carcinogens and protective
agents. However, our approach to examine the multi-pathway
tobacco carcinogenesis incorporates large body of research
findings in a genetically enriched clinical model. Our approach
could complement the GWAS approach by testing the leads
provided by high quality GWAS studies.
Materials and Methods
Ethics Statement
Approval from Hospital Ethics Committee, Tata Memorial
Centre, Mumbai was obtained before starting the study. Blood was
collected after obtaining written informed consent from patients as
well as healthy donors.
Study Population
Genotyping was carried out on 151 consecutive multiple
primary neoplasm (MPN) patients. The cases were accrued from
a registry of patients with MPN or familial cancers established at
the Tata Memorial Hospital, Mumbai, in 1996 by one of the
authors (RS). All the cases had histological or cytological
confirmation of the primary cancer and each of the cancers was
classified as TRC or non-TRC as per the IARC criteria [2]. There
was no restriction for age at diagnosis, gender or carcinogen
exposure. For defining two cancers as distinct multiple primaries,
Figure 2. Cumulative effect model of polymorphisms predis-
posing to tobacco related cancers.
doi:10.1371/journal.pone.0030013.g002
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is .2 cm of normal intervening mucosa between two primaries in
head and neck region; (b) lung as second primary if present, should
be of different histology, or be solitary and with characteristic
radiology of lung cancer; and (c) there is no evidence of
haematogenous spread. Bilateral cancers in paired organs such
as breast, ovaries or kidneys were not classified as MPN. Majority
of the MPN cases in the registry were from the western and
northern parts of India.
The cancer-free controls (n=210) were volunteers who
consented to donate blood or buccal washes for the study and
were of similar geo-ethnic background as the cases. They were
either visiting our hospital in the Preventive Oncology Department
for cancer screening (n=131) or visiting government dental
college for various non-malignant, dental ailments (n=73). A few
controls were healthy, ethnically matched workers from Mumbai
(n=6). A majority of them were tobacco users (89%).
Detailed questionnaire including ethnicity and lifetime history of
tobacco and alcohol use was obtained from all cases and controls.
Family history of cancer was obtained from majority of MPN cases
and cancer-free controls. After obtaining informed consent, 3–6 ml
of peripheral blood was collected from each subject. Exfoliated
buccal cells (mouthwashsamples) werecollectedin sterile phosphate
buffered saline from control individuals who were reluctant to give
blood (n=79). The study was approved by the Hospital Ethics
Committee, Tata Memorial Centre, Mumbai.
DNA extraction and genotyping
Genomic DNA was extracted from peripheral blood/mouth-
wash samples using phenol chloroform method standardized in
our laboratory [46]. Genotyping was done either by PCR-RFLP
(Restriction fragment length polymorphism) or by SNaPshot
method (ABI, USA). Primer sequences for PCRs were obtained
from published literature and the conditions for PCR were
standardized. The primer sequence, PCR conditions and
restriction enzymes used for RFLP are available upon request.
PCR was done in 96-well thermal cycler (ABI) in 25 mL volume
containing PCR buffer (Invitrogen), 0.2 mmol/L deoxynucleotide
triphosphates (Invitrogen), 0.5 mmol/L MgCl2 (Invitrogen), 0.25
unit Taq-Polymerase (Invitrogen), and 40 ng template DNA.
The authenticity of the PCR products was confirmed by
sequencing at least five PCR products at random on an automated
DNA sequencer (ABI Prism 3100 Avant) using the Big Dye
terminator kit (ABI Prism, Foster City, CA, USA) as per the
manufacturer’s instructions.
Multiplex genotyping
Seven polymorphisms (NAT1, NAT2, BRCA1, BRCA2, GPX,
meH and NAT3) were genotyped by multiplex PCR using
SNaPshot. The assay was performed using SNaPshot ready
reagent kit (ABI, USA). To the ready reagent, SBE primers (0.3
rmol), EXO-SAP purified PCR products were added in a total
reaction volume of 5 ml and incubated for 25 cycles of 96uC for
10 seconds, 50uC for 5 seconds and 60uC for 30 seconds. After the
reaction, samples were purified by incubating with SAP (0.5 U)
37uC for 60 minutes followed by 75uC for 15 minutes. The
purified products were run by capillary electrophoresis performed
in 96 well plates in the ABI Prism
TM 3100 genetic analyzer and
analyzed using the Genemapper software (version 3.5). For SNP
detection, the post purification products were denatured with de-
ionized formamide and Genescan
TM 120 LizH size standard
(Applied Biosystems) as per the manufacturers instructions at 95uC
for 5 minutes followed by instant chilling on ice prior to loading on
to the Sequencer. The electropherograms were depicted as two
coloured peaks corresponding to two alleles for each heterozygous
marker (SNP) or of one coloured peak for homozygous samples. As
the fragments for each SNP are of varying sizes, the peaks did not
overlap. To assure distinct recognition of closely lying peaks and
avoid any chance of overlapping, the SNPs were grouped into two
distinct panels based on the fragment size using the Primer Focus
software (ABI). The software analyzed the genotypes according to
the size and position of the alleles and accepted alleles that fall into
the predetermined panel and represented genotypes of the entire
sample set in a readily usable excel format.
Statistical Analysis
Univariate analysis. Hardy Weinberg Equilibrium in the
healthy controls was evaluated using x
2 test. Crude odds ratio and
95 percent confidence intervals were calculated for univariate
analysis. For risk estimation the genotypes were a priori classified
as homozygous low-risk or high-risk alleles based on their function
in respective pathway. For each SNP, the Odds Ratio (OR) with
its 95% Confidence Interval (CI) was estimated for the variant
allele in its heterozygous and homozygous form taking the wild
type homozygous allele as reference. Two sided p values were
reported and considered significant if p,0.05.
Statistical analysis of gene-gene/gene-environment
interactions. In order to analyze interactions between SNPs
and between SNPs and tobacco habits contributing to cancer risk,
multifactor dimensionality reduction (MDR) approach was used.
MDR is a non-parametric and genetic model free gene-gene
interaction analysis method. This method had been proposed to
overcome limitation of logistic regression in the analysis of high
order interaction models where sparse data occur frequently
[47,48]. To account for individual data with missing values,
‘Available’ MDR approach was adopted in the analysis and analysis
was performed using impute MDR in R packages [7]. Available
MDR approach uses all the individuals who have complete data
for a set of SNPs or habit variable that are included in a considered
interaction model, thus it uses different number of individuals for
each of possible interaction models. In the analysis of gene-gene or
gene-environment interactions, individuals with more than 5
missing values were excluded. The analysis was repeated 10 times
after shuffling the order of individuals and average of cross-
validation consistency (CVC), training and test accuracies are
presented. CVC is defined as the number of times a particular
interaction model is selected across 10 cross-validation datasets.
For the final selected model, we conducted odds ratio based MDR
analysis (OR MDR) [8] to get the individual genotype effects.
Supporting Information
Table S1 Univariate analysis of SNPs which do not show
significant effects.
(DOC)
Table S2 The OR MDR analysis results for the final
best model. The odds ratios having significant asymptotic
confidence interval are in bold.
(DOC)
Table S3 Linkage Disequilibrium (LD) analysis.
(DOC)
Acknowledgments
The authors wish to thank all patients and healthy volunteers who have
given blood or mouth wash samples and the staff of Cancer Genetics
Clinic, Tata Memorial Centre Memorial Hospital.
Genetic Variations in Tobacco Related MPN Patients
PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e30013Author Contributions
Conceived and designed the experiments: AK RM. Performed the
experiments: AK NJ. Analyzed the data: AK SK JN TP. Contributed
reagents/materials/analysis tools: RM RS. Wrote the paper: AK RS RM.
Patient accrual: RS.
References
1. Hung RJ, Hall J, Brennan P, Boffetta P (2005) Genetic polymorphisms in the
base excision repair pathway and cancer risk: a HuGE review. Am J Epidemiol
162: 925–942.
2. (2004) Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog
Risks Hum 83: 1–1438.
3. Balmain A, Gray J, Ponder B (2003) The genetics and genomics of cancer. Nat
Genet 33 Suppl: 238–244.
4. Jefferies S, Foulkes WD (2001) Genetic mechanisms in squamous cell carcinoma
of the head and neck. Oral Oncol 37: 115–126.
5. Kotnis A, Sarin R, Mulherkar R (2005) Genotype, phenotype and cancer: role of
low penetrance genes and environment in tumour susceptibility. J Biosci 30:
93–102.
6. Kuligina E, Reiner A, Imyanitov EN, Begg CB (2010) Evaluating cancer
epidemiologic risk factors using multiple primary malignancies. Epidemiology
21: 366–372.
7. Namkung J, Elston RC, Yang JM, Park T (2009) Identification of gene-gene
interactions in the presence of missing data using the multifactor dimensionality
reduction method. Genet Epidemiol 33: 646–656.
8. Chung Y, Lee SY, Elston RC, Park T (2007) Odds ratio based multifactor-
dimensionality reduction method for detecting gene-gene interactions. Bioinfor-
matics 23: 71–76.
9. Zheng H, Wang Z, Shi X, Wang Z (2009) XRCC1 polymorphisms and lung
cancer risk in Chinese populations: a meta-analysis. Lung Cancer 65: 268–273.
10. Kotnis A, Kannan S, Sarin R, Mulherkar R (2008) Case-control study and meta-
analysis of SULT1A1 Arg213His polymorphism for gene, ethnicity and
environment interaction for cancer risk. Br J Cancer 99: 1340–1347.
11. Jourenkova-Mironova N, Mitrunen K, Bouchardy C, Dayer P, Benhamou S,
et al. (2000) High-activity microsomal epoxide hydrolase genotypes and the risk
of oral, pharynx, and larynx cancers. Cancer Res 60: 534–536.
12. Lin TS, Huang HH, Fan YH, Chiou SH, Chow KC (2007) Genetic
polymorphism and gene expression of microsomal epoxide hydrolase in non-
small cell lung cancer. Oncol Rep 17: 565–572.
13. Zheng YL, Kosti O, Loffredo CA, Bowman E, Mechanic L, et al. (2010)
Elevated lung cancer risk is associated with deficiencies in cell cycle checkpoints:
genotype and phenotype analyses from a case-control study. Int J Cancer 126:
2199–2210.
14. Chung CC, Magalhaes WC, Gonzalez-Bosquet J, Chanock SJ (2010) Genome-
wide association studies in cancer–current and future directions. Carcinogenesis
31: 111–120.
15. Jhavar SG, Sarin R, Chopra S, Kotnis A, Mulherkar R, et al. (2005) Females
with paired occurrence of cancers in the UADT and genital region have a higher
frequency of either Glutathione S-transferase M1/T1 null genotype. J Carcinog
4: 6.
16. Jhavar S, Sarin R, Mulherkar R, Benner A, Agarwal JP, et al. (2004) Glutathione
S-transferase M1 or T1 null genotype as a risk factor for developing multiple
primary neoplasms in the upper aero-digestive tract, in Indian males using
tobacco. Oral Oncol 40: 84–91.
17. Angiero F, Berenzi A, Benetti A, Rossi E, Del Sordo R, et al. (2008) Expression
of p16, p53 and Ki-67 proteins in the progression of epithelial dysplasia of the
oral cavity. Anticancer Res 28: 2535–2539.
18. Blomquist T, Crawford EL, Mullins D, Yoon Y, Hernandez DA, et al. (2009)
Pattern of antioxidant and DNA repair gene expression in normal airway
epithelium associated with lung cancer diagnosis. Cancer Res 69: 8629–8635.
19. Marmorstein LY, Ouchi T, Aaronson SA (1998) The BRCA2 gene product
functionally interacts with p53 and RAD51. Proc Natl Acad Sci U S A 95:
13869–13874.
20. Qu T, Morimoto K (2005) X-ray repair cross-complementing group 1
polymorphisms and cancer risks in Asian populations: a mini review. Cancer
Detect Prev 29: 215–220.
21. Ramachandran S, Ramadas K, Hariharan R, Rejnish Kumar R, Radhakrishna
Pillai M (2006) Single nucleotide polymorphisms of DNA repair genes XRCC1
and XPD and its molecular mapping in Indian oral cancer. Oral Oncol 42:
350–362.
22. Hao B, Wang H, Zhou K, Li Y, Chen X, et al. (2004) Identification of genetic
variants in base excision repair pathway and their associations with risk of
esophageal squamous cell carcinoma. Cancer Res 64: 4378–4384.
23. Stern MC, Umbach DM, van Gils CH, Lunn RM, Taylor JA (2001) DNA
repair gene XRCC1 polymorphisms, smoking, and bladder cancer risk. Cancer
Epidemiol Biomarkers Prev 10: 125–131.
24. Lee SG, Kim B, Choi J, Kim C, Lee I, et al. (2002) Genetic polymorphisms of
XRCC1 and risk of gastric cancer. Cancer Lett 187: 53–60.
25. Lee JM, Lee YC, Yang SY, Yang PW, Luh SP, et al. (2001) Genetic
polymorphisms of XRCC1 and risk of the esophageal cancer. Int J Cancer 95:
240–246.
26. To-Figueras J, Gene M, Gomez-Catalan J, Pique E, Borrego N, et al. (2002)
Microsomal epoxide hydrolase and glutathione S-transferase polymorphisms in
relation to laryngeal carcinoma risk. Cancer Lett 187: 95–101.
27. Mitra AK, Singh SV, Garg VK, Sharma M, Chaturvedi R, et al. (2011)
Protective association exhibited by the single nucleotide polymorphism (SNP)
rs1052133 in the gene human 8-oxoguanine DNA glycosylase (hOGG1) with the
risk of squamous cell carcinomas of the head & neck (SCCHN) among north
Indians. Indian J Med Res 133: 605–612.
28. Hassett C, Aicher L, Sidhu JS, Omiecinski CJ (1994) Human microsomal
epoxide hydrolase: genetic polymorphism and functional expression in vitro of
amino acid variants. Hum Mol Genet 3: 421–428.
29. Amador AG, Righi PD, Radpour S, Everett ET, Weisberger E, et al. (2002)
Polymorphisms of xenobiotic metabolizing genes in oropharyngeal carcinoma.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 93: 440–445.
30. Buch SC, Nazar-Stewart V, Weissfeld JL, Romkes M (2008) Case-control study
of oral and oropharyngeal cancer in whites and genetic variation in eight
metabolic enzymes. Head Neck 30: 1139–1147.
31. Lacko M, Roelofs HM, Te Morsche RH, Voogd AC, Oude Ophuis MB, et al.
(2008) Microsomal epoxide hydrolase genotypes and the risk for head and neck
cancer. Head Neck 30: 836–844.
32. Anantharaman D, Samant TA, Sen S, Mahimkar MB (2011) Polymorphisms in
tobacco metabolism and DNA repair genes modulate oral precancer and cancer
risk. Oral Oncol 47: 866–872.
33. Paz-Elizur T, Ben-Yosef R, Elinger D, Vexler A, Krupsky M, et al. (2006)
Reduced repair of the oxidative 8-oxoguanine DNA damage and risk of head
and neck cancer. Cancer Res 66: 11683–11689.
34. Paz-Elizur T, Krupsky M, Blumenstein S, Elinger D, Schechtman E, et al.
(2003) DNA repair activity for oxidative damage and risk of lung cancer. J Natl
Cancer Inst 95: 1312–1319.
35. Nathanson KL, Weber BL (2001) ‘‘Other’’ breast cancer susceptibility genes:
searching for more holy grail. Hum Mol Genet 10: 715–720.
36. Salagovic J, Klimcakova L, Ilencikova D, Kafkova A (2011) Association of
follicular lymphoma risk with BRCA2 N372H Polymorphism in Slovak
population. Med Oncol.
37. Soumittra N, Meenakumari B, Parija T, Sridevi V, Nancy KN, et al. (2009)
Molecular genetics analysis of hereditary breast and ovarian cancer patients in
India. Hered Cancer Clin Pract 7: 13.
38. Economopoulos KP, Sergentanis TN, Zagouri F, Zografos GC (2010)
Association between p53 Arg72Pro polymorphism and colorectal cancer risk:
a meta-analysis. Onkologie 33: 666–674.
39. Jiang DK, Ren WH, Yao L, Wang WZ, Peng B, et al. (2010) Meta-analysis of
association between TP53 Arg72Pro polymorphism and bladder cancer risk.
Urology 76: 765 e761–767.
40. Bisof V, Salihovic MP, Narancic NS, Skaric-Juric T, Jakic-Razumovic J, et al.
(2010) TP53 gene polymorphisms and breast cancer in Croatian women: a pilot
study. Eur J Gynaecol Oncol 31: 539–544.
41. De Feo E, Persiani R, La Greca A, Amore R, Arzani D, et al. (2009) A case-
control study on the effect of p53 and p73 gene polymorphisms on gastric cancer
risk and progression. Mutat Res 675: 60–65.
42. Galli P, Cadoni G, Volante M, De Feo E, Amore R, et al. (2009) A case-control
study on the combined effects of p53 and p73 polymorphisms on head and neck
cancer risk in an Italian population. BMC Cancer 9: 137.
43. Dahabreh IJ, Linardou H, Bouzika P, Varvarigou V, Murray S (2010) TP53
Arg72Pro polymorphism and colorectal cancer risk: a systematic review and
meta-analysis. Cancer Epidemiol Biomarkers Prev 19: 1840–1847.
44. Tan XL, Nieters A, Hoffmeister M, Beckmann L, Brenner H, et al. (2007)
Genetic polymorphisms in TP53, nonsteroidal anti-inflammatory drugs and the
risk of colorectal cancer: evidence for gene-environment interaction? Pharma-
cogenet Genomics 17: 639–645.
45. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, et al. (1990) Prevention of
second primary tumors with isotretinoin in squamous-cell carcinoma of the head
and neck. N Engl J Med 323: 795–801.
46. Koppikar P, Mulherkar R (2006) A simple method for extraction of high
molecular weight genomic DNA from buccal cells in mouthwash. Indian Journal
of Biotechnology 5: 477–481.
47. Hahn LW, Ritchie MD, Moore JH (2003) Multifactor dimensionality reduction
software for detecting gene-gene and gene-environment interactions. Bioinfor-
matics 19: 376–382.
48. Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, et al. (2001)
Multifactor-dimensionality reduction reveals high-order interactions among
estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 69:
138–147.
Genetic Variations in Tobacco Related MPN Patients
PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e30013